TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
+46.64%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$960M
AUM Growth
+$960M
(-11%)
Cap. Flow
-$331M
Cap. Flow
% of AUM
-34.51%
Top 10 Holdings %
Top 10 Hldgs %
38.43%
Holding
146
New
23
Increased
17
Reduced
40
Closed
47
Top Buys
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$24.5M |
| 2 |
Outlook Therapeutics
OTLK
|
$19.3M |
| 3 |
Immunome
IMNM
|
$17.8M |
| 4 |
Applied Therapeutics
APLT
|
$15.2M |
| 5 |
Evolus
EOLS
|
$14.7M |
Top Sells
Sector Composition
| 1 | Healthcare | 98.03% |
| 2 | Technology | 0.94% |
| 3 | Communication Services | 0.51% |
| 4 | Real Estate | 0.32% |
| 5 | Financials | 0.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Viridian Therapeutics
VRDN
$1.59B
| $12.1M | 1.26% |
692,925
| – | – |
|
27
Zymeworks
ZYME
$1.07B
| $11.6M | 1.2% |
1,100,000
| – | – |
|
|
CRGX
28
DELISTED
CARGO Therapeutics
CRGX
| $10.4M | 1.08% |
466,809
+306,265
| +191% | +$6.84M |
|
|
ITCI
29
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $10.4M | 1.08% |
150,000
-70,000
| -32% | -$4.84M |
|
30
ANI Pharmaceuticals
ANIP
$2.06B
| $10.4M | 1.08% |
+150,000
| New | +$10.4M |
|
31
Aurinia Pharmaceuticals
AUPH
$1.58B
| $10.3M | 1.07% |
2,050,000
+1,500,000
| +273% | +$7.52M |
|
32
AstraZeneca
AZN
$255B
| $10.2M | 1.06% |
150,000
-20,000
| -12% | -$1.36M |
|
33
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $9.87M | 1.03% |
500,000
-100,000
| -17% | -$1.97M |
|
34
Cullinan Oncology
CGEM
$456M
| $9.73M | 1.01% |
571,138
-200,000
| -26% | -$3.41M |
|
35
Acadia Pharmaceuticals
ACAD
$4.34B
| $9.59M | 1% |
518,900
+404,500
| +354% | +$7.48M |
|
36
Harmony Biosciences
HRMY
$2.16B
| $9.44M | 0.98% |
281,200
+10,000
| +4% | +$336K |
|
|
DCPH
37
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $9.44M | 0.98% |
+600,000
| New | +$9.44M |
|
38
NVIDIA
NVDA
$4.15T
| $9.04M | 0.94% |
+10,000
| New | +$9.04M |
|
39
Viking Therapeutics
VKTX
$3.02B
| $8.2M | 0.85% |
+100,000
| New | +$8.2M |
|
40
Black Diamond Therapeutics
BDTX
$164M
| $8.13M | 0.85% |
1,603,200
-200,000
| -11% | -$1.01M |
|
41
Precision BioSciences
DTIL
$59.5M
| $7.99M | 0.83% |
589,569
-2,810,431
| -83% | +$6.46M |
|
42
Dianthus Therapeutics
DNTH
$781M
| $7.94M | 0.83% |
264,692
-239,550
| -48% | -$7.19M |
|
43
CRISPR Therapeutics
CRSP
$4.82B
| $7.94M | 0.83% |
116,500
-98,500
| -46% | -$6.71M |
|
44
Biohaven
BHVN
$1.71B
| $7.66M | 0.8% |
140,000
| – | – |
|
45
Arvinas
ARVN
$580M
| $7.43M | 0.77% |
180,000
+100,000
| +125% | +$4.13M |
|
46
Iovance Biotherapeutics
IOVA
$800M
| $7.41M | 0.77% |
500,000
-500,000
| -50% | -$7.41M |
|
47
Vanda Pharmaceuticals
VNDA
$279M
| $7.2M | 0.75% |
1,751,654
+1,503,464
| +606% | +$6.18M |
|
48
Cytokinetics
CYTK
$5.98B
| $7.01M | 0.73% |
100,000
-10,000
| -9% | -$701K |
|
49
Apogee Therapeutics
APGE
$2.27B
| $6.65M | 0.69% |
+100,000
| New | +$6.65M |
|
50
Ionis Pharmaceuticals
IONS
$9.64B
| $6.5M | 0.68% |
150,000
-50,000
| -25% | -$2.17M |
|